These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23209191)

  • 21. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
    Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
    Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linagliptin: in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2011 Mar; 71(5):611-24. PubMed ID: 21443284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
    Ohmura T; Hayashi N; Encinas J
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
    [No Abstract]   [Full Text] [Related]  

  • 25. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.
    Hansen HH; Hansen G; Paulsen S; Vrang N; Mark M; Jelsing J; Klein T
    Eur J Pharmacol; 2014 Oct; 741():254-63. PubMed ID: 25160746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
    BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
    Schernthaner G; Barnett AH; Emser A; Patel S; Troost J; Woerle HJ; von Eynatten M
    Diabetes Obes Metab; 2012 May; 14(5):470-8. PubMed ID: 22268497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linagliptin use in older individuals with type 2 diabetes.
    Pratley RE
    Clin Interv Aging; 2014; 9():1109-14. PubMed ID: 25083132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
    Nakaoku Y; Saito S; Yamamoto Y; Maki T; Takahashi R; Ihara M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
    Spencer NY; Yang Z; Sullivan JC; Klein T; Stanton RC
    PLoS One; 2018; 13(7):e0200249. PubMed ID: 29979777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
    J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis.
    Adhikari J; Hirai T; Kawakita E; Iwai K; Koya D; Kanasaki K
    J Diabetes Investig; 2023 Jul; 14(7):844-855. PubMed ID: 37092329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S; Sakonjo H; Jin D
    J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
    Johansen OE; Boehm BO; Grill V; Torjesen PA; Bhattacharya S; Patel S; Wetzel K; Woerle HJ
    Diabetes Care; 2014; 37(1):e11-2. PubMed ID: 24356601
    [No Abstract]   [Full Text] [Related]  

  • 38. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
    Ma M; Hasegawa Y; Koibuchi N; Toyama K; Uekawa K; Nakagawa T; Lin B; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2015 May; 14():54. PubMed ID: 25986579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
    Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.
    Nakamura Y; Tsuji M; Hasegawa H; Kimura K; Fujita K; Inoue M; Shimizu T; Gotoh H; Goto Y; Inagaki M; Oguchi K
    Hemodial Int; 2014 Apr; 18(2):433-42. PubMed ID: 24405885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.